Income Taxes, Deferred Tax Asset Valuation Adjustments (Details) - USD ($) $ in Thousands		3 Months Ended			12 Months Ended
		Dec. 31, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Valuation Allowance [Roll Forward]
Beginning balance					$ 83,378		$ 37,267		$ 18,643
Additions charged to cost and expenses		$ 38,800	$ 65,700	$ 26,900	48,211	[1]	88,108	[1]	43,286	[1]
Decreases					(47,583)		(41,997)		(24,662)
Ending balance		84,006			84,006		83,378		37,267
Deferred Tax Asset Valuation Allowance [Member]
Valuation Allowance [Roll Forward]
Beginning balance					47,142		33,557		80,186
Additions charged to cost and expenses					2,245	[2]	13,183	[3]	3,231	[4]
Decreases					(27,086)	[5]	(1,825)	[6]	(50,315)	[7]
Adjustments	[8]				2,036		2,227		455
Ending balance		$ 24,337			24,337		47,142		33,557
Valuation allowance release of foreign tax credits					(18,300)				(32,200)
Valuation allowance release of R&D credits					$ (2,300)
Additional valuation allowance recorded on foreign tax credit carryforward							$ 6,100
Utilization of foreign tax credits									$ (18,100)

[1] During the fourth quarter of 2024, the Company further executed on its product portfolio optimization initiative which resulted in an incremental inventory write-off charge of $38.8 million to the inventory carrying value. During the third quarter of 2023, the Company made the strategic decision to re-balance and narrow its product portfolio, which resulted in an incremental inventory write-off charge of $65.7 million. During the third quarter of 2022, the Company reserved an incremental $26.9 million of inventory.

[2] Increase in valuation is due primarily to net operating losses in foreign markets.

[3] Increase in valuation is due primarily to net operating losses in foreign markets and $6.1 million that was recorded on the foreign tax credit carryforward.

[4] Increase in valuation is primarily due to net operating losses in foreign markets.

[5] The decrease was due primarily to the release of the valuation allowance against $18.3 million of foreign tax credits and $2.3 million of R&D credits.

[6] The decrease was due to expiration of foreign net operating losses.

[7] The decrease was due to utilization of $18.1 million of foreign tax credits and the valuation allowance release of $32.2 million foreign tax credits.

[8] Represents the net currency effects of translating valuation allowances at current rates of exchange.